MDLA Supports Healthcare Transformation to Drive Economic Growth at the 2025 Health Summit

PT Medela Potentia Tbk actively participated in the 2025 Health Summit organized by CNBC Indonesia and the Ministry of Health of the Republic of Indonesia on Wednesday, 13 August 2025, carrying the theme “Transforming the Health Sector to Support 8% Economic Growth.”

The 8 percent economic growth target, delivered by Minister of Health Budi Gunadi Sadikin in his opening remarks, underscored the vital role of the health sector as a key driver of national economic growth.

Indonesia’s current per capita healthcare spending reaches IDR 641 trillion annually, or around USD 140 per capita—still below Malaysia (USD 432) and Singapore (USD 3,300).

“Indonesia’s healthcare industry has tremendous potential. If we can match Malaysia’s per capita healthcare spending, there is an estimated potential of USD 84 billion within the next 5–10 years,” said Mr. Budi Gunadi Sadikin.

In addition to the Minister of Health, the Health Summit 2025 was attended by the Vice Minister of Health, Dante Saksono Harbuwono; Head of the Indonesian Food and Drug Authority (BPOM), Taruna Ikrar; Director General of Pharmaceuticals and Medical Devices of the Ministry of Health, Lucia Rizka Andalusia; Secretary General of the Ministry of Health, Kunta Wibawa Dasa Nugraha; Chairman of the Indonesian Medical Association (PB IDI), Slamet Budiarto; Chairperson of the Indonesian Midwives Association (PP IBI), Ade Jubaedah; Secretary of the National Population and Family Planning Board (BKKBN), Budi Setiyono; President Director of PT Medela Potentia Tbk Krestijanto Pandji; as well as representatives from other healthcare industry players such as AstraZeneca Indonesia and DKT Indonesia.

Mr. Taruna Ikrar stated that to support the healthcare industry, BPOM has accelerated licensing processes, strengthened self-sufficiency in pharmaceutical raw materials, and prioritized the registration of both innovative and generic medicines as critical steps to bolster the healthcare ecosystem.

“We have shortened the registration process for innovative drugs from 300 days to 90 days, and for generic drugs from 150 days to 70 days. This is part of our commitment to accelerating public access to safe and high-quality medicines,” Taruna said.

MDLA’s Role in Supporting the Growth of the Healthcare Sector

As one of the leading healthcare business groups, PT Medela Potentia Tbk (MDLA) and its subsidiaries are committed to ensuring that a wide range of healthcare products are available, easily accessible, and affordable for the public through its 35 branches spanning from Aceh to Papua.

Its precise forecasting capabilities and robust logistics management enable MDLA to maintain supply across various healthcare facilities—from major hospitals to clinics in remote areas.

“With these forecasting capabilities, we can ensure service quality and medicine availability in all branches. When people are sick, they cannot wait for medicines to arrive,” said Mr. Krestijanto Pandji.

MDLA also supports the self-sufficiency of the medical device industry through its subsidiary PT Deca Metric Medica (DMM), which currently manufactures wound care products and operating room supplies in CPAKB and ISO 13485-certified facilities.

In addition, MDLA’s digital platform, GoApotik, facilitates the purchase of both prescription and over-the-counter medicines, catering to consumers who increasingly rely on online healthcare services.

“PT Medela Potentia Tbk and its subsidiaries are committed to strengthening national healthcare self-sufficiency by improving access to quality healthcare products across Indonesia,” concluded Mr. Krestijanto Pandji.